These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9203945)

  • 21. Improved diagnostic accuracy of pancreatic diseases with a combination of various novel serum biomarkers--case control study from Manipal Teaching Hospital, Pokhara, Nepal.
    Farooqui MS; Mittal A; Poudel B; Mall SK; Sathian B; Tarique M; Farooqui MH
    Asian Pac J Cancer Prev; 2012; 13(5):2171-4. PubMed ID: 22901189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
    Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
    Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.
    Oue N; Sentani K; Noguchi T; Ohara S; Sakamoto N; Hayashi T; Anami K; Motoshita J; Ito M; Tanaka S; Yoshida K; Yasui W
    Int J Cancer; 2009 Nov; 125(10):2383-92. PubMed ID: 19670418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
    Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
    Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
    Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
    Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of tumor markers in determining resectability of pancreatic cancer.
    Schlieman MG; Ho HS; Bold RJ
    Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer.
    Ding W; Wang J; Wang F; Wang G; Wu Q; Ju S; Cong H; Wang H
    Clin Biochem; 2013 Oct; 46(15):1590-4. PubMed ID: 23792260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
    Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum fatty acid synthase as a marker of pancreatic neoplasia.
    Walter K; Hong SM; Nyhan S; Canto M; Fedarko N; Klein A; Griffith M; Omura N; Medghalchi S; Kuhajda F; Goggins M
    Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2380-5. PubMed ID: 19723916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
    Shimizu K; Ueda Y; Yamagishi H
    Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.